That's it in nutshell. These folks who are talking about "fundamentals" have no idea of the real opportunity here - it's just their way of saying that the stock has gone up too fast.
Apologies for my garbled heading, which results from eliminating a reference to the publication in question, assuming that it would get me dumped into the SPAM file.
Note that the lead story on the Summary page stirs expectations for idelalasib by hinting that Gilead is "set to reveal further details" of the recently halted trial in Tuesday's ASH presentation. (Unlikely in my view - the numbers are the numbers.) It also dramatizes the results by noting that the trial was halted because "the drug was proving so effective" and raises the possibility of idelalasib being serous competition for ibrutinib. I suspect that this story may be attracting shortsellers to PCYC. Or at least scaring away some longs.
In truth, the idelalasib trial compared the results of the drug + Rituxan vs a placebo +Rituxan, and was halted because the combo therapy was more effective. The significant PCYC trials use ibrutinib as a monotherapy. In my view ibrutinib is poised to replace Rituxan as a first line treatment for CLL. I don't think we'll get much of a pop from the Monday presentations. In fact, we may get another selloff from disappointed trader whereupon I would look to add more shares.
Ah, The King of Imaginary Traders emerges! We can be sure that when this stock eventually peaks, this clown will claim to have shorted it at exactly that point.
The shorts who are on here trying to pick up a few scraps would obviously have done better by going long since the stock is now a hair's breadth away from its high. To sit on a short while it goes 7 points underwater also seems like a questionable strategy. (Stops anyone?) The "terrible side effects" story is bogus. The only question is whether neratinib is superior to Herceptin, which has been amply demonstrated in the recent study.
Yes, and that was a steal for JNJ. Let's hope he goes for $5 bilion on this one.
I didn't buy a whole bunch, but I added some. We can speculate about the reasons for the selloff today, but it's pointless. Retail investors always assume the sellers have some secret inside information. Actually, if you wanted to unload shares, this would be a singularly clumsy way to do it. Maybe Eddie Lampert needed to raise cash. Maybe one of Steven A Cohen's Picasso's didn't make the reserve price. Company still looks great to me. (Incidentally, if a large holder really wanted to unload a position, they would drive the stock up at the open and then walk it down gently.)
I lost two friends to CLL. At endgame, they were both on Campath, an expensive drug ($60,000 per year) which does not work for CLL. Compared to which an expensive drug which works would be a bargain. Incidentally, Campath was an MS drug which Genzyme pulled in order to replace it with a more expensive MS drug.
Well, I just reread the ASH abstracts, which confirm my belief that this is a revolutionary drug for CLL and Waldenstrom's. I am not expecting any surprises, but I added shares on today's weakness.
A dangerous stock to be out of, I think. Although if you want to add to your base position on the dips and sell on the pops, that would make sense. But just hope you're overweight when the CLL approval is announced.
Well, a really smart daytrade would have been to buy it a the open today and hold it. You could have made a few points daytrading REGN at around 60 in 2011 (right after it a major runup). But the smarter trade would have been to buy it and hold it.
And if you didn't have a buy order in which got executed on that desperate little move where they took out the stops of the daytrading longs, I'd be nervous going into the weekend short this stock.
But, in case you haven't noticed, there are very few shares being offered. And since we're sitting just off the high of the day, I'd say you're underwater at the moment on your short positions. In fact, the ask is at a new high right now. This would make me nervous if I were a short.
Well, AFFY is an illustration of the fact that, as with ARIA, the initial stages of a drug's distribution are dangerous. If you're going to kill people, it's better to do it in the trials.
Dec. 2016. And the implication that cheaper Zytiga will replace Xtandi is wrong. By next year, all oncologists will be using Xtandi first. Zytiga will be used when Xtandi stops working. JNJ's best hope - which would take some time and a lot of legal dollars to pull off - would be to create a new drug by combining Zytiga with the Aragon drug.
And why not? The larger world is beginning to appreciation the meaning of that trial.
Well, for the benefit of his poor shareholders, it would be nice if he could stop equivocating and give a clear answer.. My personal opinion is that this is a negotiating ploy in order to write a contract extension with Ford. As I've said before, his only credential in the area of software is My Ford Touch, a dubious achievement.
Oh ye of little faith. Yes, this sluggardly behavior is really all about Mullaly. When this is resolved either way the stock will rally. No one wants to be holding a large position in Ford when Mullaly jumps ship. And many are shorting it in anticipation of this. Ironically, Mullaly was supposed to retire soon anyway and has established a clear plan for succession. The last time I looked (October sales) the F150 was outselling the Silverado 2 to 1. The hedge funds like GM, nevertheless, since they think that the departure of the government will remove an overhang. I think Ackerman is an unimaginative beancounter. (Seen any Volt advertising lately? That was a strange little engineering marvel to hang your hat on.)